Jan 30, 2024
Immutep Quarterly Activities Report Q2 FY24
Jan 04, 2024
First Patient Dosed in Trial Evaluating Efti and the Anti-PD-L1 Therapy BAVENCIO® in Metastatic Urothelial Cancer
Dec 20, 2023
Immutep Receives Constructive Regulatory Feedback on TACTI-004 Registrational Trial in Metastatic Non-Small Cell Lung Cancer
Dec 07, 2023
Immutep Receives A$2.6 million R&D Tax Incentive from French Government
Nov 22, 2023
Immutep Announces Site Expansion for INSIGHT-003 Phase I Trial
Nov 09, 2023
Immutep Completes Enrollment in TACTI-003 Phase IIb Trial of Efti and KEYTRUDA® in First Line Metastatic or Recurrent Head and Neck Squamous Cell Carcinoma
Nov 06, 2023
Immutep Announces Completion of the Safety Lead-In and Opening of the Randomized Phase II of the AIPAC-003 Phase II/III Trial in Metastatic Breast Cancer
Nov 02, 2023
Immutep Announces New Biomarker Data from TACTI-002 Phase II in First Line Non-Small Cell Lung Cancer
Nov 01, 2023
Immutep to Participate in November Investor Events
Oct 30, 2023
Immutep Quarterly Activities Report Q1 FY24
Oct 25, 2023
Immutep Receives ~A$1.13 Million R&D Tax Incentive
Oct 24, 2023
Immutep Reports Promising Clinical Data from INSIGHT-003 Trial at ESMO Congress 2023
